FIELD: medicine, pharmaceutics.
SUBSTANCE: pharmaceutical composition with kappa-opioid agonistic activity, demonstrating an analgesic effect in accordance with the first version contains 9-(2-morpholinoethyl)-2-(4-fluorophenyl)imidazo[1,2-α]benzimidazole dihydrochloride as an active component, and an isotonicity corrigent, selected from salts of organic and inorganic acids, polyols, amino acids, as auxiliary substances. The composition can additionally contain a co-solvent, a corrigent of the solution pH, a cryoprotector, and an antioxidant. In accordance with the second version the pharmaceutical composition contains 9-(2-morpholinoethyl)-2-(4-fluorophenyl)imidazo[1,2-α]benzimidazole dihydrochloride as an active component, and a co-solvent, selected from ethyl alcohol, glycerol, propylene glycol, benzylbenzoate, benzyl alcohol, ethyloleate and fatty oils, including olive oil and peach oil as auxiliary substances. The composition can additionally contain an isotonicity corrigent, a corrigent of the solution pH, a cryoprotector, and an antioxidant.
EFFECT: invention provides the pharmaceutical composition in an injection form with kappa-opioid agonistic activity without narcogenic potential, demonstrating the fast relief of pain syndrome.
12 cl, 5 dwg, 3 tbl, 4 ex
Title | Year | Author | Number |
---|---|---|---|
PHARMACEUTICAL COMPOSITION IN SOLID FORM WITH ANALGESIC ACTIVITY | 2013 |
|
RU2545861C1 |
ANTICANCER PHARMACEUTICAL COMPOSITIONS AND METHOD OF TREATING BREAST CANCER | 2015 |
|
RU2581022C1 |
HIGH-STABLE PHARMACEUTICAL FORMULATION OF LYOPHILISATE OF 3-OXYPYRIDINE AND METHYLPYRIDINE DERIVATIVES AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | 2012 |
|
RU2504376C1 |
ANTITUMOUR ANTHRAFURANDIONE AND BASED PHARMACEUTICAL COMPOSITIONS | 2014 |
|
RU2554939C1 |
METHOD OF PRODUCING BORTEZOMIB LYOPHILIZATE AND A PHARMACEUTICAL COMPOSITION CONTAINING BORTEZOMIB IN FORM OF A STABLE LYOPHILIZED PRODUCT OBTAINED BY SAID METHOD | 2018 |
|
RU2696854C1 |
BORTEZOMIB LYOPHILIZATE PRODUCTION METHOD AND THE BORTEZOMIB CONTAINING PHARMACEUTICAL COMPOSITION IN THE FORM OF STABLE LYOPHILIZATED PRODUCT PRODUCED BY SAID METHOD | 2017 |
|
RU2659160C1 |
PHARMACEUTICAL COMPOSITION OF NEUROPROTECTIVE ACTION FOR PARENTERAL APPLICATION ON BASIS OF HEXAMETHYLENEDIAMINE BIS-(N-MONOSUCCINYL-L-GLUTAMIL-L-LYSINE) IN LYOPHILIZED DOSAGE FORM | 2017 |
|
RU2678203C2 |
STABLE PHARMACEUTICAL COMPOSITION BASED ON ACTINOMYCIN D FOR INJECTIONS | 2014 |
|
RU2587716C2 |
LIPOSOMAL AGENT BASED ON UBIQUINOL AND PREPARATION METHOD THEREOF | 2015 |
|
RU2605616C1 |
ANTIVIRAL PHARMACEUTICAL COMPOSITION CONTAINING FAVIPIRAVIR AND AN AMINO ACID, MEDICINAL PRODUCT CONTAINING SAID COMPOSITION, AND APPLICATION THEREOF FOR TREATING AND/OR PREVENTING VIRAL INFECTIONS | 2021 |
|
RU2783282C1 |
Authors
Dates
2015-09-20—Published
2013-10-02—Filed